Navigation Links
Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines

Publication in September issue of Nature Methods Shows Application of

Bioinformatics tools to Identify The Most Powerful Matrix Attachment

Regions Applied to Boost Transgene Expression.

GENEVA, Switzerland, Aug. 21 /PRNewswire/ -- Researchers at Selexis SA and The University of Lausanne have reported the identification of novel high-performance Genetic Elements also known as matrix attachment regions (or MARs). Data are presented using these novel high-performance Genetic Elements for increased gene expression in mammalian cells. This research, published online August 5 and in the September issue of the journal Nature Methods, demonstrates that using bioinformatics analysis, researchers computed putative novel genetic elements from the human genome and confirmed through cloning experiments that these newly identified genetic elements could significantly and stably increase transgene expression in mammalian cells when compared to previously known genetic elements.

"Having the ability to identify and apply the most powerful genetic elements for use in the rapid development of high-performance cell lines further improves our already powerful technology and service offering," said Dr. Igor Fisch, CEO of Selexis. "Selexis has been applying this experimental approach to identify of our most productive Selexis Genetic Elements, and in fact, we are planning the introduction of a new class of Selexis Genetic Elements later this year. These new elements will be smaller and more powerful and are showing even greater performance in boosting antibody expression in CHO cells," continued, Dr. Fisch. "We are confident our existing and new licensees and cell line development customers will benefit from this new offering."

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services to speed the development of high performance mammalian cell lines. The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development(SM) process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

Selexis Genetic Elements(TM) and SURE Cell Line Development SM are trademarks of Selexis SA.

Copyright©2007 PR Newswire.
All rights reserved

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis
5. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
6. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
7. GlycoFi announces the first production of antibodies with human glycosylation in yeast
8. NHGRI announces new sequencing targets
9. CHAVI announces international search for genes affecting HIV response
10. NHGRI announces latest sequencing targets
11. MUHC announces a transplant first in Quebec
Post Your Comments:
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology: